Meeting
2015 ASCO Annual Meeting
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcome of bevacizumab (bev)-based treatment in patients with metastatic colorectal cancer (mCRC): Results from TRIBE and FIRE3 trials.
Authors
Yu Sunakawa
University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA
Yu Sunakawa , Sebastian Stintzing , Volker Heinemann , Chiara Cremolini , Alfredo Falcone , Shu Cao , Dongyun Yang , Wu Zhang , Shinichi Yamauchi , Yan Ning , Stefan Stremitzer , Satoshi Matsusaka , Anish Parekh , Shannon Graver , Angela Mendez , Satoshi Okazaki , Rita Elkhoueiry , Stefan J. Scherer , Fotios Loupakis , Heinz-Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3552)
DOI
10.1200/jco.2015.33.15_suppl.3552
Abstract #
3552
Poster Bd #
44
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Macrophage polarization related gene variants to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (bev) in combination with FOLFIRI.
First Author: Yu Sunakawa
Poster
2014 ASCO Annual Meeting
Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial.
First Author: Dominik Paul Modest
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Tissue factor: A link between metastatic colorectal cancer and thrombosis in patients in the CALGB (Alliance)/SWOG 80405 trial.
First Author: Sandra Algaze
Poster
2018 ASCO Annual Meeting
Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC).
First Author: Rahul K Das